Effect of Panax Ginseng on the Cognitive Performance in Alzheimer’s Disease
|ClinicalTrials.gov Identifier: NCT00391833|
Recruitment Status : Completed
First Posted : October 24, 2006
Last Update Posted : October 24, 2006
|Condition or disease||Intervention/treatment||Phase|
|Alzheimer's Disease Memory Decline||Drug: Panax Ginseng||Phase 1 Phase 2|
Alzheimer’s disease (AD) is characterized by a progressive decline of memory and intellectual abilities, interfering activity in daily living, the overall quality of life, and ultimately leads to death. Although pharmacologic treatments are currently approved for treating mild- to moderate AD using acetylcholinesterase inhibitors (ACEI) or memantine, the NMDA antagonist, for the advanced stage of AD, the therapeutic efficacies need to be further improved.
For millennia, ginseng or its components have been used to treat medical conditions, and the pharmacologic effects have been demonstrated in cardiovascular, endocrine and immune system (Attele et al., 1999). In means of memory and learning, a number of studies suggested that ginseng can attenuate learning deficits of damaged or ageing brains in rodent models (Kennedy et al., 2003; Zhao and McDaniel, 1998; Nitta et al., 1995). In studies with human healthy participants, correspondently, both acute and chronic dosage of ginseng increased the cognitive performance (Kennedy et al., 2001; Kennedy et al., 2003; D’Angelo et al., 1986; Sorensen and Sonne, 1996).
In this study, we we will investigate the contribution of ginseng treatment in increasing the cognitive improvement of AD patients. In addition, we will test various bio-markers and hematopoietic progenitor cell count in those included patients using their blood samples. Patients with AD as well as memory decline will be included
|Study Type :||Interventional (Clinical Trial)|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Study Start Date :||April 2004|
|Estimated Study Completion Date :||October 2005|
- Cognitive performances monitored by MMSE and Alzheimer’s disease assessment scales.
- Biomarkers including hematopoietic progenitor cell count.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00391833
|Study Chair:||Manho Kim, MD, PhD||Department of Neurology, Seoul National University Hospital|